This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cirz, R. T. Articles by Romesberg, F. E. Search for Related Content PubMed PubMed Citation Articles by Cirz, R. T. Articles by Romesberg, F. E.

Induction and Inhibition of Ciprofloxacin Resistance-Conferring Mutations in Hypermutator Bacteria

Department of Chemistry, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, California 92037

Received 13 May 2005/ Returned for modification 1 August 2005/ Accepted 12 September 2005

The emergence of drug-resistant bacteria poses a serious threat to human health. Bacteria often acquire resistance from a mutation of chromosomal genes during therapy. We have recently shown that the evolution of resistance to ciprofloxacin in vivo and in vitro requires the induction of a mutation that is mediated by the cleavage of the SOS repressor LexA and the associated derepression of three specialized DNA polymerases (polymerase II [Pol II], Pol IV, and Pol V). These results led us to suggest that it may be possible to design drugs to inhibit these proteins and that such drugs might be coadministered with antibiotics to prevent mutation and the evolution of resistance. For the approach to be feasible, there must not be any mechanisms through which bacteria can induce mutations and acquire antibiotic resistance that are independent of LexA and its repressed polymerases. Perhaps the most commonly cited mechanism to elevate bacterial mutation rates is the inactivation of methyl-directed mismatch repair (MMR). However, it is unclear whether this represents a LexA-independent mechanism or if the mutations that arise in MMR-deficient hypermutator strains are also dependent on LexA cleavage and polymerase derepression. In this work, we show that LexA cleavage and polymerase derepression are required for the evolution of clinically significant resistance in MMR-defective Escherichia coli. Thus, drugs that inhibit the proteins responsible for induced mutations are expected to efficiently prevent the evolution of resistance, even in MMR-deficient hypermutator strains.

This article has been cited by other articles:

• Bacher, J. M., Schimmel, P. (2007). An editing-defective aminoacyl-tRNA synthetase is mutagenic in aging bacteria via the SOS response. Proc. Natl. Acad. Sci. USA 104: 1907-1912 [Abstract] [Full Text]  
• Cirz, R. T., Jones, M. B., Gingles, N. A., Minogue, T. D., Jarrahi, B., Peterson, S. N., Romesberg, F. E. (2007). Complete and SOS-Mediated Response of Staphylococcus aureus to the Antibiotic Ciprofloxacin. J. Bacteriol. 189: 531-539 [Abstract] [Full Text]  
• Cirz, R. T., O'Neill, B. M., Hammond, J. A., Head, S. R., Romesberg, F. E. (2006). Defining the Pseudomonas aeruginosa SOS Response and Its Role in the Global Response to the Antibiotic Ciprofloxacin.. J. Bacteriol. 188: 7101-7110 [Abstract] [Full Text]